• CENTRALISATION OF SAMPLE COMPOUNDS IN TOULOUSE PROVIDES GREATER EFFICIENCY FOR SANOFI'S SMALL MOLECULE DRUG DISCOVERY EFFORTS
• LATEST DISPENSING TECHNOLOGY WILL HELP OPTIMISE COMPOUND ACCESS ACROSS GLOBAL RESEARCH SITES

Hamburg, Germany, 18 December 2019: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi.

Evotec has had a successful track record of managing Sanofi's powder compounds at its Toulouse site since 2015. Under the terms of the new agreement, Sanofi will transfer its liquid compounds to Evotec in Toulouse over the next 2 years. Evotec will house the Sanofi compound collections in Toulouse combining central storage efficiency with sample delivery supported by next generation, cutting-edge technologies e.g. acoustic tubes. This expanded strategy will deliver cost efficiencies through the minimisation of redundancies and realisation of synergies between sites.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "We are pleased to expand our relationship with Sanofi. It's a significant step forward to synergise and centralise core drug discovery processes for better efficiency and to enhance our sample management expertise with the latest dispensing technologies. We look forward to continuing to deliver the highest quality sample management service for Sanofi and for our other clients."

About Evotec's Sample Management
The demand for organised data storage and management concepts to maintain, collect and distribute compounds has grown significantly. Evotec is uniquely qualified in delivering its customers small and large molecule library management needs through over a decade of being the world's leading sample management operation. Starting from a single site in South San Francisco in 2004 primarily serving the US, Evotec expanded its operational presence in sample management in 2013, and again in 2015, by adding capacity and capabilities in Branford, Connecticut and Toulouse, France. These facilities are strategically positioned to support the strong presence of Evotec's drug discovery services across the USA and Europe.

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to and follow us on Twitter .

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec SE:
Gabriele Hansen, SVP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255,